Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile

Keyu Li(Sichuan University), Bruce A. Keyt, Paul R. Hinton(IGM Biosciences (United States)), Stephen F. Carroll(IGM Biosciences (United States)), Gene Li(IGM Biosciences (United States)), Rodnie Rosete(IGM Biosciences (United States)), Dean Ng(IGM Biosciences (United States)), Umesh S. Muchhal(IGM Biosciences (United States)), Min Chai(IGM Biosciences (United States)), Poonam Yakkundi(IGM Biosciences (United States)), Angus M. Sinclair(LabGenius (United Kingdom)), Liqin Liu(MacroGenics (United States)), Rui Yun(IGM Biosciences (United States)), Maya F. Kotturi(Alameda Hospital)
Blood
November 15, 2022
Cited by 10


Related Papers